Aggregated News
Aastrom Biosciences Inc (ASTM.O) said a mid-stage trial of its treatment for congestive heart failure was put on hold after a patient died, sending its shares down 24 percent.
The patient died at home after being released from the hospital following treatment in the trial, the company said in a statement.
The cause of the patient's death has not yet been determined and is the subject of a pending investigation at the clinical site, Aastrom said, adding that an independent data safety monitoring board will also assess the circumstances of the event.
Aastrom has temporarily suspended enrollment and patient treatment in the trial, called IMPACT-DCM.
The trial was evaluating the surgical delivery of autologous cells directly into the human heart muscle for the treatment of congestive heart failure.
Patients in the trial were treated with Aastrom's cardiac repair cells, a product that contains stem and early progenitor cells produced from the patient's own bone marrow.
Shares of the company were down 24 percent at 32 cents in pre-market trade Friday. They closed at 42 cents Thursday on Nasdaq.
The patient died at home after being released from the hospital following treatment in the trial, the company said in a statement.
The cause of the patient's death has not yet been determined and is the subject of a pending investigation at the clinical site, Aastrom said, adding that an independent data safety monitoring board will also assess the circumstances of the event.
Aastrom has temporarily suspended enrollment and patient treatment in the trial, called IMPACT-DCM.
The trial was evaluating the surgical delivery of autologous cells directly into the human heart muscle for the treatment of congestive heart failure.
Patients in the trial were treated with Aastrom's cardiac repair cells, a product that contains stem and early progenitor cells produced from the patient's own bone marrow.
Shares of the company were down 24 percent at 32 cents in pre-market trade Friday. They closed at 42 cents Thursday on Nasdaq.